GH Research PLC
GH Research PLC (GHRS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GHRS · as of Jun 8, 2026
Key Statistics
Explore GH Research PLC Data
ghrs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 100.0%
The GHRS analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $40.57, representing +99.70% upside from the current price of $20.32.
Competitors & Peers
ghrs competitorsGHRS
ABUS
KURA
LENZ
NBTX
PROKStock Performance
Full HistoryAbout GH Research PLC
GH Research PLC a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Me…
what is gh research plc · ghrs stock overview · gh research plc company profile · who is gh research plc ceo · ghrs NASDAQ · gh research plc headquarters · gh research plc business segments
About Stock Overview & Key Data
GH Research PLC (GHRS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 25, 2021. As of the latest trading session, GHRS stock price is $20.32, with a market capitalization of $1.4B. The stock has returned +48.23% over the past 12 months and +59.91% year-to-date.
According to 9 Wall Street analysts, the consensus rating for GH Research PLC stock is Buy, with an average 12-month price target of $40.57. In fiscal year 2025, GH Research PLC reported revenue of — and net income of -$48.3M. For detailed data — including GH Research PLC revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, GH Research PLC (GHRS) stock price is $20.32. The stock is traded on NASDAQ under the ticker symbol GHRS. The 52-week range is $11.32 – $25.94.